Study from Yale Cancer Biologists Identifies Chromatin Regulator WDR5 as Possible Drug Target in Triple-Negative Breast Cancer
A new study from Yale Cancer Center scientists has identified the chromatin regulator WDR5 as a possible new drug target in triple negative breast cancer.
- December 03, 2021
Two Yale Department of Pathology graduate students were recently awarded prestigious Ruth L. Kirschstein Predoctoral Individual National Research Service Awards (F31) from the National Cancer Institute of the National Institutes of Health (NIH).
- September 01, 2021
In honor of the 50th Anniversary of the National Cancer Act, Dr. Anna Arnal Estapé shares her motivation for pursuing a career in cancer research.
- February 25, 2021
When lung cancer and breast cancer relapse, they often metastasize in the brain. The tumors that arise in the brain develop novel characteristics, differences that oft en confer resistance to existing drug therapies and create opportunities for new detection and treatment approaches for Yale Cancer Center researchers.
- May 03, 2019
Katerina Politi, PhD and Don Nguyen, PhD, members of the Signal Transduction Research Program at Yale Cancer Center (YCC), have received a 5-year, nearly $4 million National Cancer Institute (NCI) grant to support Lung Cancer research.
- April 27, 2019
New technique by Yale Cancer Center scientists may improve detection and treatment of advanced brain cancer
In a new study, Yale Cancer Center scientists have demonstrated a powerful method to analyze how tumor cells are altered as they metastasize to the brain.
- February 28, 2017Source: Yale Daily News
In a recent study, Yale researchers discovered a mechanism co-opted by lung cancer cells in order to spread to the brain. Lung cancer is the No. 1 cause of cancer-related deaths, killing more people than breast, colon and prostate cancers worldwide, according to Don Nguyen, a professor of pathology at the Yale School of Medicine and a senior author of the study. The most frequentluy diagnosed form of lung cancer is lung adenocarcinoma, which originates in the lungs but is most dangerous after it has migrated to other parts of the body in a process known as metastasis. LUAD metastasis to the brain is often deadly and can leave survivors with heightened risk of relapse and a far lower quality of life, Nguyen said. Metastasis is one of cancer’s many “black boxes” Nguyen said, in that very little is known about the mechanisms that allow this process to take place.
- February 15, 2017
More people die of lung cancer each year than breast, colon, and prostate cancers combined. One particularly lethal form of the disease is lung adenocarcinoma or LUAD, which afflicts both smokers and non-smokers. In many patients diagnosed with LUAD, tumors cells have already spread to the brain, leading to decreased quality of life and low survival rates. A Yale Cancer Center research team conducted a study to determine how those tumor cells manage to grow outside the lungs.
- February 09, 2017
A Yale-led research team identified how insulin-producing cells that are typically destroyed in type 1 diabetes can change in order to survive immune attack. The finding may lead to strategies for recovering these cells in diabetic patients, said the researchers.
- April 22, 2016
Congratulations Dr. Don Nguyen, who was awarded a Department of Defense IDEA Award! The award provides 3 years of support for "conceptually innovative, high-risk/high-reward research.” With this award, Dr. Nguyen’s laboratory will explore how novel therapies can be used to prevent metastasis from lung cancer. Previously, Dr. Nguyen identified a gene regulator critical for breast cancer metastasis to the lung.